This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Xipamide is a diuretic indicated in the treatment of edema.
- Generic Name
- Xipamide
- DrugBank Accession Number
- DB13803
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Xipamide (DB13803)
- Weight
- Average: 354.81
Monoisotopic: 354.0441058 - Chemical Formula
- C15H15ClN2O4S
- Synonyms
- Xipamida
- Xipamide
- Xipamidum
- External IDs
- BE 1293
- BE-1293
- MJF 10,938
- MJF 10938
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Edema •••••••••••• ••••• ••••••• ••••••• •••• •••••• Used in combination to treat Edema Combination Product in combination with: Triamterene (DB00384) •••••••••••• ••••• ••••••• •••• •••••• Treatment of High blood pressure (hypertension) •••••••••••• ••••• ••••••• ••••••• •••• •••••• Used in combination to treat Mild to moderate hypertension Combination Product in combination with: Triamterene (DB00384) •••••••••••• ••••• ••••••• •••• •••••• Used as adjunct in combination to treat Severe hypertension Combination Product in combination with: Triamterene (DB00384) •••••••••••• ••••• ••••••• •••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Xipamide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy. Abaloparatide Abaloparatide may increase the hypotensive activities of Xipamide. Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Xipamide. Acebutolol Acebutolol may increase the hypotensive activities of Xipamide. Aceclofenac The therapeutic efficacy of Xipamide can be decreased when used in combination with Aceclofenac. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image NEOTRI Xipamide (10 mg) + Triamterene (30 mg) Tablet, film coated Oral 2006-07-01 2020-10-15 Germany 
NEOTRI Xipamide (10 mg) + Triamterene (30 mg) Tablet, film coated Oral 2006-07-01 2020-10-15 Germany NEOTRI Xipamide (10 mg) + Triamterene (30 mg) Tablet, film coated Oral 2006-07-01 Not applicable Germany
Categories
- ATC Codes
- C03BA10 — Xipamide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Anilides
- Direct Parent
- Benzanilides
- Alternative Parents
- 4-halobenzoic acids and derivatives / Benzenesulfonamides / Salicylamides / Benzamides / Benzenesulfonyl compounds / m-Xylenes / Benzoyl derivatives / M-chlorophenols / Chlorobenzenes / 1-hydroxy-2-unsubstituted benzenoids show 11 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 3-chlorophenol / 3-halophenol / 4-halobenzoic acid or derivatives / Aminosulfonyl compound / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Benzamide / Benzanilide show 30 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4S9EY0NUEC
- CAS number
- 14293-44-8
- InChI Key
- MTZBBNMLMNBNJL-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22)
- IUPAC Name
- 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide
- SMILES
- CC1=CC=CC(C)=C1NC(=O)C1=CC(=C(Cl)C=C1O)S(N)(=O)=O
References
- General References
- DIMDI Product Information: NEOTRI (xipamide and triamterene) oral tablet [Link]
- External Links
- ChemSpider
- 24795
- 11371
- ChEBI
- 135499
- ChEMBL
- CHEMBL517199
- ZINC
- ZINC000000538538
- Wikipedia
- Xipamide
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Tablet Oral 40 mg Tablet, film coated Oral Tablet Oral 10 MG Tablet Oral 20 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0246 mg/mL ALOGPS logP 2.73 ALOGPS logP 3 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 6.17 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 109.49 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 90.62 m3·mol-1 Chemaxon Polarizability 34.43 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0029000000-1ef49c35fb65cf0903cf Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-2109000000-a41b011d87a07ba695db Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0519000000-73b79b6877c5730bfe12 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0w29-1609000000-87e798f9cfa634cc3bd3 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0fsl-5922000000-e77b6fffc1f6dfa0e42a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9300000000-86657bc56adbaeaef665 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.98274 predictedDeepCCS 1.0 (2019) [M+H]+ 176.34074 predictedDeepCCS 1.0 (2019) [M+Na]+ 182.51433 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:48 / Updated at May 21, 2021 10:23